StockNews.com Begins Coverage on Regulus Therapeutics (NASDAQ:RGLS)

StockNews.com assumed coverage on shares of Regulus Therapeutics (NASDAQ:RGLSFree Report) in a report released on Sunday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

Several other research analysts have also recently weighed in on RGLS. HC Wainwright restated a buy rating and set a $9.00 price target on shares of Regulus Therapeutics in a report on Monday, March 25th. Canaccord Genuity Group reduced their target price on Regulus Therapeutics from $12.00 to $11.00 and set a buy rating for the company in a report on Tuesday, March 19th. Wells Fargo & Company increased their price target on Regulus Therapeutics from $2.00 to $3.00 and gave the company an equal weight rating in a research report on Wednesday, March 13th. Leerink Partnrs reissued an outperform rating on shares of Regulus Therapeutics in a research report on Monday, March 18th. Finally, SVB Leerink started coverage on Regulus Therapeutics in a research report on Monday, March 18th. They set an outperform rating and a $6.00 target price for the company. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of Moderate Buy and an average price target of $7.25.

Read Our Latest Analysis on Regulus Therapeutics

Regulus Therapeutics Stock Down 2.9 %

Shares of NASDAQ:RGLS opened at $2.72 on Friday. The business’s 50 day moving average is $1.81 and its 200 day moving average is $1.50. Regulus Therapeutics has a 12-month low of $0.82 and a 12-month high of $3.79. The stock has a market cap of $178.05 million, a price-to-earnings ratio of -1.71 and a beta of 1.56.

Regulus Therapeutics (NASDAQ:RGLSGet Free Report) last issued its quarterly earnings data on Thursday, March 21st. The biopharmaceutical company reported ($0.40) earnings per share for the quarter, meeting the consensus estimate of ($0.40). As a group, equities research analysts expect that Regulus Therapeutics will post -0.52 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. increased its holdings in Regulus Therapeutics by 21.4% in the 1st quarter. Vanguard Group Inc. now owns 3,678,334 shares of the biopharmaceutical company’s stock worth $1,096,000 after acquiring an additional 648,121 shares during the last quarter. Federated Hermes Inc. purchased a new position in shares of Regulus Therapeutics in the first quarter worth about $8,656,000. Northern Trust Corp raised its position in shares of Regulus Therapeutics by 42.9% in the first quarter. Northern Trust Corp now owns 168,172 shares of the biopharmaceutical company’s stock valued at $50,000 after purchasing an additional 50,518 shares during the period. Renaissance Technologies LLC lifted its stake in shares of Regulus Therapeutics by 498.2% during the 1st quarter. Renaissance Technologies LLC now owns 133,400 shares of the biopharmaceutical company’s stock valued at $40,000 after buying an additional 111,100 shares in the last quarter. Finally, Dimensional Fund Advisors LP bought a new position in Regulus Therapeutics in the 3rd quarter worth approximately $54,000. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Regulus Therapeutics Company Profile

(Get Free Report)

Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease.

Read More

Analyst Recommendations for Regulus Therapeutics (NASDAQ:RGLS)

Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.